Effect of Angelica gigas Nakai extract on hepatic damage in rats
Purpose: To determine the antioxidant and hepatoprotective effects of decursin and decursinol angelate (D/DA) isolated from Angelica gigas Nakai (AGN).
Methods: The 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity of D/DA was assessed in a rat model using blood tests, western blotting, and histopathological analyses to identify the pharmaceutical effects of D/DA on liver enzymes and liver morphology.
Results: The DPPH scavenging activity of D/DA was 47.11 μg/mL. Administration of D/DA to carbon tetrachloride (CCl4)-treated rats led to a decrease (13.59 %) in the total liver mass of control rats. Decursin and decursinol angelate also lowered the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), but increased the concentrations of antioxidant enzymes in the liver, including catalase (CAT) and glutathione peroxidase (GPx). Histological examination revealed that D/DA also reduced hepatocellular damage in the rats.
Conclusion: D/DA from AGN has significant anti-hepatotoxic and antioxidant activities, and thus, is a potential herbal drug for treating liver damage.
Keywords: Decursin, Decursinol angelate, Antihepatotoxicity, Antioxidant, Angelica gigas Nakai
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.